Avalon GloboCare Corp., a global developer of cell-based technologies and therapeutics, has formed a new wholly owned U.S. subsidiary, Avactis Biosciences, Inc., which will focus on accelerating commercial activities related to its Chimeric Antigen Receptor (CAR)-T technologies, and will integrate and optimize the company’s global scientific and clinical resources. CAR-T is a novel and revolutionary cancer immunotherapy that involves genetically modifying T cells to activate the immune system to...